Huons BioPharma has been recognized by the local community for its efforts to promote a family-friendly workplace culture and achieve gender equality within the company.
Huons BioPharma announced on Thursday that it recently received an award for excellence in gender equality at the “2025 Jecheon City Gender Equality Week Commemoration Ceremony” held in Jecheon City, North Chungcheong Province.
The Gender Equality Week Commemoration Ceremony is an annual event held by local governments during Gender Equality Week, which takes place in the first week of September. It aims to achieve equality in daily life and foster a social atmosphere where both men and women can grow together, promoting equality in accordance with the Basic Act on Gender Equality.
Huons BioPharma is a competitive company in the botulinum toxin product sector (Liztox in trademark name and Hutox in export name). Following the expansion of its third factory within Bio Valley last year, the company continues to contribute to sustained job creation and employment growth, according to the company.
Specifically, Huons BioPharma actively implements: hiring career-interrupted women as regular employees; expanding recruitment of marginalized groups, including people with disabilities; creating a corporate culture and safe working environment supporting work-life balance; operating welfare spaces for employees; improving the working environment for female employees; and operating internship programs linked to hiring with local high schools and universities through industry-academic cooperation, the company said..
“Huons BioPharma strives for equal opportunity in skill development regardless of gender and promotes a balanced life between work and family,” CEO Kim Young-mok said. “We will continue to build a community where everyone communicates harmoniously and empathizes, ensuring all employees enjoy equal opportunities.”
Related articles
- Huons Global posts record quarterly revenue despite profit decline in Q2
- Huons Global sees steady growth in exports, R&D despite flat Q1 revenue
- Huons showcases aesthetic innovations at Dubai Derma 2025
- Huons’ Chinese BTX partner postpones launch of Hutox by 1 year
- Huons Biopharma partners with KIST to develop dry macular degeneration eye drops
- Huons Biopharma partners with VERNI Aesthetics to advance fat-decomposition injection MRC101
- Huons’ smart insulin pen DIA:CONN P8 improves glycemic control in clinical study
- Huons picked for national project to stabilize orphan and essential drug supply
- Huons secures rights to Therapex’s targeted NSCLC therapy, TRX-211
- Huons' Q3 operating profit up 14% on export rebound, CMO growth
- Huons Global's Q3 operating profit jumps 42% as pharma, toxin exports drive growth
